A
Atbin Djamshidian
Researcher at Innsbruck Medical University
Publications - 108
Citations - 3230
Atbin Djamshidian is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Parkinson's disease & Medicine. The author has an hindex of 28, co-authored 91 publications receiving 2525 citations. Previous affiliations of Atbin Djamshidian include UCL Institute of Neurology & University of London.
Papers
More filters
Journal ArticleDOI
Exenatide and the treatment of patients with Parkinson’s disease
Iciar Aviles-Olmos,John Dickson,Zinovia Kefalopoulou,Atbin Djamshidian,Peter J. Ell,Therese A. Söderlund,Peter S. Whitton,Richard K. Wyse,Tom Isaacs,Andrew J. Lees,Patricia Limousin,Thomas Foltynie +11 more
TL;DR: These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD.
Journal ArticleDOI
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours
Sean S. O'Sullivan,Sean S. O'Sullivan,Kit Wu,Marios Politis,Andrew D. Lawrence,Andrew Evans,Subrata K. Bose,Atbin Djamshidian,Andrew J. Lees,Paola Piccini +9 more
TL;DR: The heightened response of striatal reward circuitry to heterogeneous reward-related visual cues among a group of patients with different impulsive-compulsive behaviours is consistent with a global sensitization to appetitive behaviours with dopaminergic therapy in vulnerable individuals.
Journal ArticleDOI
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
Iciar Aviles-Olmos,John Dickson,Zinovia Kefalopoulou,Atbin Djamshidian,Joshua Kahan,Peter J. Ell,Peter S. Whitton,Richard K. Wyse,Tom Isaacs,Andrew J. Lees,Patricia Limousin,Thomas Foltynie +11 more
TL;DR: Patients previously exposed to exenatide had an advantage over the control group of patients, and this provides strong encouragement for the further study of this drug as a potential disease modifying agent in Parkinson's disease.
Journal ArticleDOI
Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis.
Barbara Kornek,Maria K. Storch,Jan Bauer,Atbin Djamshidian,Robert Weissert,Erik Wallstroem,Andreas Stefferl,Fritz Zimprich,Tomas Olsson,Christopher Linington,Manfred Schmidbauer,Hans Lassmann +11 more
TL;DR: The study of the distribution of the pore-forming subunit of neuronal (N)-type voltage-gated calcium channels in the lesions of multiple sclerosis and EAE found that alpha(1B) was accumulated within axons and axonal spheroids of actively demyelinating lesions, suggesting that calcium influx through voltage-dependent calcium channels is one possible candidate mechanism for axonal degeneration in inflammatory demYelinating disorders.
Journal ArticleDOI
Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study.
Verena Rass,Ronny Beer,Alois Josef Schiefecker,Mario Kofler,Anna Lindner,Philipp Mahlknecht,Beatrice Heim,Victoria Limmert,Sabina Sahanic,Alex Pizzini,Thomas Sonnweber,Ivan Tancevski,Christoph Scherfler,Laura Zamarian,Rosa Bellmann-Weiler,Günter Weiss,Atbin Djamshidian,Stefan Kiechl,Klaus Seppi,Judith Loeffler-Ragg,Bettina Pfausler,Raimund Helbok +21 more
TL;DR: In this article, the authors evaluated neurological signs and diseases by detailed neurological examination and a predefined test battery assessing smelling disorders (16-item Sniffin Sticks test), cognitive deficits (Montreal Cognitive Assessment), QoL (36-item Short Form), and mental health (Hospital Anxiety and Depression Scale, Posttraumatic Stress Disorder Checklist-5).